Abstracts tagged "prevention"

Abstract Number: 2608 • ACR Convergence 2025
Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis
Maria Dons¹, Charlotte Näslund-Koch², Morten Sengeløv³, Sofie Bøgh-Sørensen³, Kristoffer Skaarup³, Marianne Bengtson Løvendorf⁴, Filip Davidovski³, Anne Marie Reimer Jensen³, Brittany Weber⁵, Lise Lotte Gluud⁶, Claus Zachariae², Lone Skov² and Tor Biering-Sørensen³, ¹Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, ²Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ³Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, ⁴Department of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ⁵Brigham and Women's Hospital, DEDHAM, MA, ⁶Gastro Unit, Copenhagen University Hospital – Hvidovre, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic risk factor. Individuals with psoriasis have a high prevalence of MASLD, yet…
Abstract Number: 0210 • ACR Convergence 2025
Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Akhil Sood¹, Srijana Davuluri², Sheila Haidar³, De Suan Huang³, April Ochoa³, Christy Bill¹ and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Stanford Health Care, Palo Alto, CA
Background/Purpose: Despite guideline recommendations, recombinant zoster vaccine (RZV) uptake remains low among immunocompromised individuals younger than 50 years of age, notably those with rheumatoid arthritis…
Abstract Number: 1274 • ACR Convergence 2025
Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
Andres Perez Hurtado¹, Jose Ivorra Cortes², ELENA GRAU GARCIA³, Miguel Simeo Vinaixa⁴, Iago Alcantara Alvarez⁴, Belen Villanueva Manes⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Pablo Muñoz Martinez⁴, Laura mas sanchez⁸, Berta López Montesinos⁹, Lucía Lacruz Pérez¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ²Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Pediatric Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Juvenile idiopathic arthritis is the most common group of inflammatory rheumatic diseases in childhood. Its early onset and the immunosuppressive treatments used to control…
Abstract Number: 2613 • ACR Convergence 2025
Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis
Giulia Corte¹, Koray Tascilar², armin Atzinger³, Alp Temiz², Melek Yalcin Mutlu⁴, Rita Noversa de Sousa⁵, Maria Gabriella Raimondo⁶, Andreas Ramming⁷, Sara Bayat², Michael Sticherling⁸, Torsten Kuwert⁹, Christian Schmidkonz⁹, Georg Schett¹⁰ and Filippo Fagni¹¹, ¹- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ³Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, erlangen, ⁵Department of Internal Medicine ³, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, ⁶Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine ³, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Department of Dermatology, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany
Background/Purpose: 68Ga-FAPI-04 PET/CT reveals fibroblast activation in vivo and is increasingly used to assess rheumatic diseases, including inflammatory arthritides. (1,2) We previously demonstrated that the…
Abstract Number: 0211 • ACR Convergence 2025
Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration
Alexandra Do¹, Lisa Matsumoto¹, Cherish Wilson², Gary Tarasovsky³, gabriela Schmajuk⁴ and Jennifer Barton⁵, ¹Oregon Health and Science University, Portland, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, ⁴University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁵VA Portland Health Care System/OHSU, Portland, OR
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) are used to treat many rheumatologic diseases by modulating the patient’s immune system. However, patients on DMARDs are more susceptible…
Abstract Number: 1294 • ACR Convergence 2025
Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
Kristina Ciaglia¹ and Magan Fosso², ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Pneumococcal vaccination is critical in patients with childhood-onset systemic lupus erythematosus (cSLE) due to their immunocompromised status and increased susceptibility to serious infections. Despite…
Abstract Number: 2653 • ACR Convergence 2025
First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes
Ana Paula Luppino-Assad¹, Renata P Mello², Ana C Medeiros-Ribeiro³, Nadia E Aikawa⁴, Sandra G Pasoto³, Leonard V Kupa⁵, Renata Miossi⁶, Percival D Sampaio-Barros⁶, Eduardo Borba⁷, Eloisa Bonfa⁷ and Clovis Artur Silva⁸, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, ⁷Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Systemic sclerosis (SSc) patients are at higher risk of herpes zoster (HZ) due to underlying immune dysregulation and immunosuppressive therapies. Vaccination is a key…
Abstract Number: 0260 • ACR Convergence 2024
National Survey on Patient’s Knowledge and Drivers of Human Papillomavirus (HPV) Vaccination in Immune-mediated Inflammatory Diseases (IMIDs)
Tiphaine Goulenok¹, Arthur Mageau², Chrystelle Francois¹, Eric HACHULLA³, Thomas Papo² and Karim Sacré², ¹Assistance Publique Hôpitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France, ³CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France., LILLE, France
Background/Purpose: Persistent human papillomavirus (HPV) infection is the cause of cervical cancer. Patients with immune-mediated inflammatory diseases (IMIDs) exposed to immunosuppressive therapy are at increased risk…
Abstract Number: 1907 • ACR Convergence 2024
Community-Engaged Curriculum Development Using Racial Justice and Biomedical Lenses to Address COVID-19 Vaccine Hesitancy in Black Individuals with Rheumatologic Conditions
Eseosa Osaghae¹, Greta Sirek², Tonya Roberson³, Mia Chandler⁴, Ariel Childs⁵, Monica Crespo-Bosque⁶, Gina Curry⁷, Amar Dhand⁸, Mary Dollear⁹, Alice Eggleston¹⁰, Nnenna Ezeh², Dieufort Fleurissaint¹¹, Denice Garrett¹², Gail Granville¹³, Muriel Jean-Jacques¹, Elena Losina², Holly Milaeger¹, Lutfiyya Muhammad¹⁴, Mary Ann Nelson¹⁵, Chisa Nosamiefan¹⁶, Bisola Ojikutu¹⁷, Neil Pillai¹, Marie Jacques Toussaint¹⁸, Mary Beth Son¹⁹, Ana Valle², Jessica Williams²⁰, Michael York²¹, Karen Mancera-Cuevas²², Candace Feldman² and rosalind Ramsey-Goldman¹, ¹Northwestern University, Chicago, IL, ²Brigham and Women's Hospital, Boston, MA, ³Governors State University College of Health and Human Services, University Park, IL, ⁴Boston Children’s Hospital, Boston, MA, ⁵Vital CxNs, Boston, MA, ⁶Boston Medical Center, Boston, MA, ⁷University of Chicago Pritzker School of Medicine, Chicago, IL, ⁸Brigham and Women’s Hospital, Boston, MA, ⁹Lupus Society of Illinois, Chicago, IL, ¹⁰Alliance Chicago, Chicago, IL, ¹¹True Alliance Center, Inc, Boston, MA, ¹²Action for Bridgeport Community Development, Inc., Bridgeport, CT, ¹³Women of Courage, Inc, Boston, MA, ¹⁴Northwestern Feinberg School of Medicine, Chicago, IL, ¹⁵Mission Hill Health Movement Inc, Roxbury, MA, ¹⁶The Labalaba Foundation for Lupus Awareness and Advocacy, South Weymouth, MA, ¹⁷Harvard Medical School, Brigham and Women’s Hospital, Boston Public Health Commission,, Boston, MA, ¹⁸True Alliance Center, Inc., Boston, MA, ¹⁹Boston Children's Hospital, Brookline, MA, ²⁰Emory School of Medicine, Atlanta, GA, ²¹Boston University, Boston, MA, ²²National Health Council, Washington, DC
Background/Purpose: Despite the efficacy of COVID-19 vaccines and the benefits for individuals with rheumatic conditions, racial inequities in uptake persist. We initiated a trial that…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 1957 • ACR Convergence 2024
Assessing Left Ventricular Hemodynamic Forces in Systemic Sclerosis Patients: Pilot Study
Aïcha Kante¹, Andreea Afana², Damien Sène³, Valérie Bousson⁴, Trecy Goncalves⁵, Edouard Ballout⁵, Solenn Toupin⁵, Jean-Guillaume Dillinger⁶, William Bigot³, Valentin Pagis⁷, Karine Champion³, Ruxandra burlacu⁷, stephane mouly³, Patrick Henry⁶, Theo Pezel⁶ and Cloé Comarmond³, ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ²Department of Cardiology, University of Medicine and Pharmacy Craiova, Craiova, Romania, ³Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁴Department of Radiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, ⁵Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, France, ⁶Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, ⁷Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease marked by inflammation, microvascular changes and fibrosis. Cardiac comorbidities are the leading cause of mortality. Early…
Abstract Number: 0417 • ACR Convergence 2024
Contraception in Community Rheumatology Practices
Megan Clowse¹, Julie Chiesa², Pamela Freeman³, Bansari Gujar⁴, Kelley Jones⁵, Richard Jones⁶, Ann Marslett⁷, Amanda Snyderman⁵ and Leah Zulig⁸, ¹Duke University, Chapel Hill, NC, ²InfoDirectors, Durham, NC, ³Rheumatology Associates of Central Florida, Orlando, FL, ⁴Rheumatology Associates of Baltimore, Towson, MD, ⁵Duke University School of Medicine, Durham, ⁶Clinic for Rheumatic Diseases, Northport, AL, ⁷Rheumatology Associates of Baltimore, Baltimore, MD, ⁸Duke University School of Medicine, Durham, NC
Background/Purpose: Most prior studies of contraception in women with rheumatic disease focused on academic centers. In this study of non-academic rheumatology practices, we sought to…
Abstract Number: 1958 • ACR Convergence 2024
Hemodynamic Forces: A Novel Cardiac MRI Parameter to Assess Cardiac Involvement in Sarcoidosis Patients
Aïcha Kante¹, Andreea Afana², Damien Sène³, Karine Champion³, Valentin Pagis⁴, William Bigot³, Véronique Delcey⁵, Amanda Lopes³, Abdellatif Tazi⁶, Blanca Amador Borrero⁴, Bruno Crestani⁷, Claire Baladi⁸, Valérie Bousson⁹, Trecy Goncalves¹⁰, Edouard Ballout¹⁰, Solenn Toupin¹⁰, stephane mouly³, Jean-Guillaume Dillinger¹¹, Patrick Henry¹¹, Theo Pezel¹¹ and Cloé Comarmond³, ¹Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Université Paris Cité, Paris, Ile-de-France, France, ²Department of Cardiology, University of Medicine and Pharmacy Craiova, Craiova, Romania, ³Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁴Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, France, ⁵Department of Infectious diseases, Lariboisère University Hospital, Paris, Ile-de-France, France, ⁶National Reference Center for Histiocytoses, Department of Pulmonology, AP-HP, Saint-Louis Hospital, Paris, France, ⁷National Reference Center for Rare Pulmonary Diseases, Department of Pulmonology, AP-HP, Bichat Hospital, Paris, Ile-de-France, France, ⁸Université d’Angers, Department of Cardiology, University Hospital of Angers, Angers, France, ⁹Department of Radiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France, ¹⁰Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, France, ¹¹Department of Cardiology, Lariboisiere Hospital, (Assistance Publique des Hôpitaux de Paris, AP-HP), Paris, Ile-de-France, France
Background/Purpose: Cardiac sarcoidosis (CS) is an underdiagnosed condition characterized by the formation of non-caseating granuloma in the myocardium, potentially leading to arrhythmia, acute heart failure,…
Abstract Number: 0446 • ACR Convergence 2024
Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications
Kathryn Kompa¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Methotrexate (MTX) and mycophenolate (MMF) are two common medications for both lupus (SLE) and rheumatoid arthritis (RA). Both medications are contraindicated in pregnancy, necessitating…
Abstract Number: 2096 • ACR Convergence 2024
A Model Based on Clinical and Molecular Data Predcits the Risk of Total Joint Replacement Progression in Knee OA Patients from the OAI
Ignacio Rego-Perez¹, Alejandro Duran-Sotuela², Jorge Vazquez-Garcia², Cristina Ruiz-Romero³, Valentina Calamia², Carlota Fraga-Seijas⁴, Vanesa Balboa-Barreiro⁵, Sara Relaño², María C. De Andrés², Lucia Lourido², Rocio Paz-Gonzalez², Patricia Quaranta², Patricia Fernández-Puente², Nicola Veronese⁶, Natividad Oreiro⁷ and francisco J Blanco⁸, ¹Instituto de Investigacion Biomedica de A Coruña-SERGAS, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, A Coruña, Spain, ³INIBIC - CHUAC, A Coruña, Spain, ⁴INIBIC, A Coruña, Spain, ⁵Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁶Geriatric Unit, Department of Internal Medicine and Geriatrics, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy, A Coruña, Spain, ⁷CHUAC, La Coruna, Galicia, Spain, ⁸INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: There is a need to design models that predict the risk of total joint replacement (TJR) in patients with knee osteoarthritis (OA). Our aim…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].